Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Amit Munshi is a highly accomplished biopharmaceutical executive with over three decades of extensive experience in global drug development, commercialization, and corporate strategy. He is recognized as a strategic leader with a strong track record of building and leading high-growth life sciences companies. Throughout his career, Munshi has held numerous leadership positions, including CEO roles where he successfully executed company turnarounds, secured significant financing, and orchestrated major M&A deals. His expertise spans various therapeutic areas, with a recent focus on cutting-edge fields like RNA medicines and immunology. He is currently the President and CEO of ReNAgade Therapeutics, a company at the forefront of RNA technology.
Amit Munshi's work history includes a series of influential roles in various companies. Here is a detailed list of his professional journey:
As President and CEO of Arena Pharmaceuticals, Amit Munshi orchestrated a remarkable corporate turnaround. He strategically refocused the company's R&D pipeline on high-potential assets in immunology and cardiovascular disease, significantly increasing its value and culminating in a landmark $6.7 billion all-cash acquisition by Pfizer in 2022.
Currently serves as the President and CEO of ReNAgade Therapeutics, placing him at the vanguard of RNA medicine innovation. He leads the company's mission to develop a comprehensive RNA platform that integrates delivery, coding, editing, and gene insertion capabilities to treat diseases on a global scale.
While serving as President and CEO of Kythera Biopharmaceuticals, he was instrumental in the commercial readiness and successful launch of KYBELLA®, the first-in-class, FDA-approved injectable drug for submental fullness. His leadership contributed to the company's eventual acquisition by Allergan for $2.1 billion.
Throughout his tenure at major pharmaceutical companies like Amgen, AstraZeneca, and Chiron, he held key commercial leadership roles, driving the growth and market success of numerous blockbuster products across multiple continents.
Claremont Graduate University - Peter F. Drucker and Masatoshi Ito Graduate School of Management - Year 1991
University of California, Riverside - Year 1986
Highperformr Signals uncover buying intent and give you clear insights to target the right people at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
Orna Therapeutics is a biotechnology company pioneering a new class of fully engineered circular RNA (oRNAâ„¢) therapies. Unlike traditional linear mRNA, Orna's circular RNA is designed to be more stable and produce larger quantities of therapeutic proteins, potentially leading to more effective treatments. The company's platform focuses on developing groundbreaking therapies for a range of diseases, with initial programs in cancer, including in situ CAR (isCAR) therapies, and genetic disorders.
Get verified emails, phone numbers, and LinkedIn profile details
Discover contacts with similar roles, seniority, or companies
Uncover insights like skills, work history, social links, and more
Explore contacts in-depth — from verified emails and phone numbers to LinkedIn activity, job changes, and more — all in one powerful view.
Highperformr AI helps you surface the right people and enrich your CRM with live, accurate contact insights so your teams can connect faster and close smarter.
Thousands of contacts — including decision-makers, influencers, and ICP matches — are just a search away.
Thousands of companies, including, are just a search away.